AlphAIalphai — Financial news for AI agents
StockNASDAQ · US · USDHealthcare · Biotechnology

$ANTX

AN2 Therapeutics, Inc.

Price · $ANTXvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $ANTX in the last 7 days.

Insider · 30dAll trades →
Buys
$12K
1 txs
Sells
$213K
2 txs
Readnour Robin Shane2× · $213K
10b5-1 share of filings67%
See all $ANTX insider activity →
Top stories · $ANTXMore →
AUG 12·rttnews.com

AN2 Therapeutics Stock Climbs To 52-Week High Despite Wider Q2 Loss

AN2 Therapeutics (ANTX) reported Q2 2026 results with a wider net loss of $8.2 million, or $0.18 per share, versus $6.5 million, or $0.21 per share, in Q2 2025. R&D rose to $6.0 million from $3.2 million, while G&A fell to $2.9 million from $4.0 million. Cash was $79.9 million. The stock hit a 52-week high at $7.19.

AUG 11·SEC EDGAR 8-K

AN2 Therapeutics, Inc. (ANTX): Results of Operations and Financial Condition

AN2 Therapeutics, Inc. (ANTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights Expanding Phase 2 study start-up activities to support global trial of oral epetraborole in polycythemia vera Enrollment ongoing in Phase 2 investigator-initi

ANTX sentiment & insider activity

Recent ANTX coverage spans financial news, insider activity and earnings.

In the last 30 days, ANTX insiders filed 3 SEC Form 4 transactions — 1 purchase ($12K) and 2 sales ($213K). The most active reporter was Readnour Robin Shane with 2 filings. 67% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving ANTX

  • Small insider purchase may signal confidence but limited material impact.

    SEC EDGAR · Sep 2, 2026

  • The stock’s 52-week high move is tied to improved cash runway and specific upcoming IND and enrollment milestones, despite widening losses.

    rttnews.com · Aug 12, 2026

  • Near-term catalyst is IND filing in Q3 2026 and Phase 2 enrollment starting Q4 2026, with additional Phase 2 progress in M. abscessus and Chagas.

    SEC EDGAR 8-K · Aug 11, 2026

  • Routine corporate governance vote results; limited direct fundamental change, but can affect near-term sentiment around board/audit continuity.

    SEC EDGAR 8-K · Jun 8, 2026

  • Insider open-market sale is a modest negative signal, but size is small and lacks a new fundamental catalyst.

    SEC EDGAR · Jun 2, 2026

alphai scores every news story that mentions ANTX with an AI model for sentiment and relevance, and aggregates insider trades from AN2 Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ANTX

Score
AUG 11$ANTXMedSEC EDGAR 8-K

AN2 Therapeutics, Inc. (ANTX): Results of Operations and Financial Condition

AN2 Therapeutics, Inc. (ANTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights Expanding Phase 2 study start-up activities to support global trial of oral epetraborole in polycythemia vera Enrollment ongoing in Phase 2 investigator-initi

6 min read
JUN 8$ANTXLowSEC EDGAR 8-K

AN2 Therapeutics, Inc. (ANTX): Submission of Matters to a Vote of Security Holders

AN2 Therapeutics, Inc. (ANTX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001880438 0001880438 2026-06-03 2026-06-03 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 03,

3 min read
APR 9$ANTXLowTipRanks

AN2 Therapeutics Launches New $80 Million ATM Program

AN2 Therapeutics (ANTX) has established a new $80 million at-the-market (ATM) stock sale program with Jefferies to issue common stock. This move replaces a previous ATM agreement with TD Securities, under which the company had raised approximately $20 million. The company's stock currently holds a Hold rating with a $3.50 price target from analysts, while TipRanks' AI Analyst Spark rates ANTX as Neutral due to weak financial performance despite positive technicals.

2 min read
MAR 9$ANTXMedBioSpace

AN2 Therapeutics Announces $40 Million Private Placement Financing

AN2 Therapeutics, a clinical-stage biopharmaceutical company, announced a private placement financing expected to generate approximately $40 million in gross proceeds. The financing includes the sale of common stock and pre-funded warrants to new and existing institutional investors, including Coastlands Capital, Commodore Capital, and Vivo Capital. The proceeds will support the company's development of novel small molecule therapeutics utilizing its boron chemistry platform.

4 min read
JAN 30$ANTXMedTipRanks

AN2 Therapeutics adjusts leadership roles and executive compensation

AN2 Therapeutics (ANTX) has appointed Sarah Williams as Principal Accounting Officer with an increased salary, effective February 1, 2026. Simultaneously, CFO Lucy Day's salary will be reduced as part of the company's cost-saving efforts, while her other employment terms remain largely unchanged. The company's stock currently holds a "Hold" rating with a $1.00 price target based on analyst forecasts.

3 min read

Related tickers

More in Biotechnology